ACRIN Announces New Clinical Trial
The aim of ACRIN 6678, “Fluorodeoxyglucose (FDG) as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung Cancer,” is to determine whether positron emission tomography (PET) can effectively and consistently measure quantitative changes in FDG uptake during chemotherapy resulting in an early indication about the effectiveness of therapy in patients with advanced non-small cell lung cancer.
The trial led by Wolfgang Weber, MD, of UCLA Medical Center, will be one of the first clinical trials initiated by the Oncology Biomarker Qualification Initiative (OBQI) a new and innovative collaboration among the National Cancer Institute, Federal Drug Administration and Centers for Medicare and Medicaid Services designed to qualify biomarkers for use in clinical trials – and ultimately speed new drug therapies to cancer patients. Some OBQI projects such as this one will be funded through public-private partnerships coordinated under the Foundation for the National Institutes of Health and executed through the auspices of the NIH Biomarker Consortium.
More than 10 sites throughout the United States are expected to enroll 228 patients in two years.
Click here to view a protocol summary, the full protocol, and the protocol specific application.
Contact protocol manager Donna Hartfeil at dhartfeil@phila.acr.org or by phone at (215) 717-2765 with questions.